Nov 13 (Reuters) - resTORbio, Inc. ::RESTORBIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.30.
Full Article
July 25 (Reuters) - resTORbio, Inc. ::RESTORBIO, INC. - ALL DOSES WERE WELL-TOLERATED.RESTORBIO, INC. - RTB101 10 MG ONCE DAILY HAD A COMPARABLE SAFETY PROFILE TO PLACEBO.RESTORBIO ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 2B TRIAL OF RTB101.RESTORBIO, INC. - GREATER TORC1 INHIBITION WITH RTB101 10 MG IN COMBINATION WITH EVEROLIMUS 0.1 MG DID NOT MEET PRIMARY ENDPOINT.RESTORBIO, INC. - PHASE 2B IS SECOND STUDY IN WHICH RTB101 10 MG ONCE DAILY WAS OBSERVED TO BE WELL-TOLERATED.RESTORBIO, INC. - PHASE 2B HAS SUCCESSFULLY DEFINED A DOSE, RTB101 10 MG ONCE DAILY, TO BE EVALUATED IN FUTURE PIVOTAL STUDIES.
Full Article
July 11 (Reuters) - resTORbio, Inc. ::RESTORBIO ANNOUNCES SCIENCE TRANSLATIONAL MEDICINE PUBLICATION OF PHASE 2A DATA SHOWING IMPROVEMENT IN IMMUNE FUNCTION AND DECREASED INFECTION RATES IN PEOPLE AGED 65 YEARS AND OLDER.RESTORBIO - CO'S TORC1 INHIBITORS WERE ASSOCIATED WITH STATISTICALLY SIGNIFICANT DECREASE IN INCIDENCE OF ALL INFECTIONS IN OLDER PEOPLE.RESTORBIO - BASED ON RESULTS OF THE PHASE 2A STUDY, CO CONDUCTING PHASE 2B CLINICAL TRIAL & 16-WEEK TOPLINE DATA ARE EXPECTED TO BE REPORTED IN Q3 2018.
Full Article
May 10 (Reuters) - resTORbio, Inc. ::RESTORBIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.46.Q1 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.
Full Article
March 29 (Reuters) - Restorbio, Inc. ::RESTORBIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $5.11.CASH AND CASH EQUIVALENTS WERE $53.3 MILLION AS OF DECEMBER 31, 2017.EXPECTS CURRENT CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017, TO BE SUFFICIENT TO FUND ITS OPERATING EXPENSES THROUGH 2020.
Full Article
Earnings vs. 
Estimates